Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State

NCT02223065 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02223065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02223065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2014
Enrollment
36 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus